Enitiatebio Nets One Hundred Million of CNY in Series A Round
Enitiatebio (Chinese: 启元生物) completed one hundred million of CNY （USD） in Series A financing round on August 31, 2022. This round was led by Momentum Venture (Chinese: 时节创投), followed by Taikun Fund (Chinese: 泰鲲基金), LPSCO (Chinese:临平国投) and Hangzhou Jintou Industrial Fund (Chinese:杭州金投产业基金). StartPointAdvisors (Chinese: 行远致同) acted as the exclusive financial advisor for this transaction.
Enitiatebio was co-founded by Viva Vision (Chinese: 维眸生物) and Betta Biomedical Industry Fund (Chinese: 贝达生物医药产业基金) at the end of 2020. The company was dedicated to developing innovative drugs for treating autoimmune diseases.
The competitors of the company include 3SBIONIC(Chinese: 三生制药), CarthroniX, and Angany.
Briefing Sep 21, 2022 10:38 AM
· Healthcare
Weiyou Gene Nets Tens of Millions of CNY in Series Pre-A Round
Briefing Sep 16, 2022 11:10 PM
· Healthcare
NaviSeed Nets Tens of millions of CNY in Angel Round
In-depth
Briefing Sep 13, 2022 05:30 PM
· Healthcare
Nuwacell Nets Hundreds of Mns of CNY in Series A
Briefing Jun 28, 2022 09:56 AM
· Healthcare
And platinum medicine b7h4x4-1bb bispecific antibody were approved by FDA for new drug research
Aug 29, 2022 05:45 PM
Apr 22, 2021 03:11 PM
Research
Technology, Healthcare, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Briefing Jun 28, 2022 09:54 AM
· Healthcare
Fosun pharma and Amgen have reached cooperation to accelerate the commercialization of two innovative drugs in China
Briefing Jun 28, 2022 09:50 AM
· Healthcare
It is expected to achieve functional cure of chronic hepatitis B! GSK antisense therapy phase IIB positive clinical results
Briefing Jun 24, 2022 11:15 AM
· Healthcare
F-star to be acquired by China biopharmaceutical with USD 161million
Briefing Jun 24, 2022 11:07 AM
· Healthcare
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
Insight
Healthcare
15 Companies to Watch in September 2022- Healthcare
Editor's note: We at EqualOcean tracked the major funding rounds or industry events that took place in China's healthcare space in September 2022. And the following is a list of deals that we have selected for you, based on a number of criteria, including the funding amount, the financial backers, and the segments in which the startups operate.
Sep 30, 2022 12:32 PM
Briefing Jun 24, 2022 10:46 AM
· Healthcare
East China medicine "liraglutide" goes to sea
Briefing Jun 23, 2022 06:25 PM
· Healthcare
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Healthcare
Ubrigene Bags Hundreds of Mns of CNY in Series C Financing Round
Ubrigene, dedicated to providing one-stop CDMO services for cell and gene therapies, will continue to improve its management system and incubate more specialized technology platforms with the fresh proceeds.
Sep 27, 2022 06:35 PM
Briefing Jun 23, 2022 06:24 PM
· Healthcare
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
Briefing Jun 23, 2022 10:36 AM
· Healthcare
Germany Merck "cetuximab" new indications for head and neck squamous cell carcinoma approved in China
Briefing Jun 23, 2022 10:27 AM
· Healthcare
Yanye new crown drug 3CL protein inhibitor has been suspended approval
Briefing Jun 23, 2022 10:24 AM
· Healthcare
Sanofi Greater China will be headed by Shi Wang, and Henting he will become the global head of the digital business unit
See more
Read next
Insight
In-depth
Insight
In-depth
Insight
In-depth